Compounded semaglutide stability data — looking for input

josh_phd_bmore said:

Following this thread I went back and re-read the extension data properly.

Same experience, arrived at from the opposite direction. The detail I would add is minor and it is already implied above.

josh_phd_bmore said:

Following this thread I went back and re-read the extension data properly.

There is a second half to this that has not been said yet. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

The figures, for anyone assembling their own picture. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

Worth separating that from compounded supply, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Following on from josh_phd_bmore — and this may be the naive question:

Whether anyone has held at a sub-maximal dose long term and kept the result, or whether the maintenance data only exists at 2.4mg?

raj_cambridge said:

If you are going to change something, change one thing and give it long enough to express itself.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The objection nobody has made: this only works if the measurement is doing what we assume it is doing, and that assumption has not been tested here.